Merck (NYSE:MRK) received Health Canada approval for ENFLONSIA, its RSV preventive therapy for infants. The authorization expands Merck's presence in the respiratory and infectious disease space in ...

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

Merck (MRK) closed at $110.42 in the latest trading session, marking a +1.92% move from the prior day. The stock outperformed ...

Merck's Keytruda should continue growing its sales until it faces a patent cliff in 2028. The company is developing other medicines to deal with mounting competition. Merck is also a solid choice for ...

Merck's biggest cash cow could soon face competition from two drugs in development. However, the company is working on ways to get around this potential headwind. These are all good things, none of ...

Michael Rosenblatt, dean of Tufts University School of Medicine (TUSM), yesterday morning announced his decision to step down effective Dec. 20. He will take up the newly created position of chief ...